Johanna Friedl-Naderer
Known title: Chief Commercial OfficerCIK: 0001915598
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Transaction History
| DYN | ▼ Sell | Open Market | 185 | $3K | 9/8/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 900 | $22K | 9/4/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 226 | $6K | 8/13/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 145 | $3K | 6/16/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 228 | $4K | 5/13/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 148 | $2K | 3/5/2026 | View on chart |
| DYN | ▲ Buy | Grant | 60,000 | $0 | 2/12/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 144 | $3K | 12/5/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 144 | $2K | 9/5/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 894 | $12K | 9/4/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 146 | $2K | 6/5/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 143 | $2K | 3/13/2025 | View on chart |
| DYN | ▲ Buy | Grant | 37,800 | $0 | 12/4/2024 | View on chart |
| DYN | ▲ Buy | Grant | 58,400 | $0 | 9/3/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 1,482 | $34K | 3/3/2023 | View on chart |
| VIR | ▲ Buy | Grant | 60,000 | $0 | 2/22/2023 | View on chart |
| VIR | ▲ Buy | Grant | 90,000 | $0 | 3/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Dyne Therapeutics highlighted in recent healthcare stock coverage
Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.
Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.